Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the
Zacks Style Scores, helps address this issue for us.
Below, we take a look at
United Therapeutics (, a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. UTHR Quick Quote UTHR - Free Report)
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. United Therapeutics currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of
Zacks #1 Rank Stocks here >>> Set to Beat the Market?
In order to see if UTHR is a promising momentum pick, let's examine some Momentum Style elements to see if this drugmaker holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For UTHR, shares are up 2.59% over the past week while the Zacks Medical - Drugs industry is up 5.06% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 9.84% compares favorably with the industry's 7.3% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of United Therapeutics have risen 30.11%, and are up 30.6% in the last year. In comparison, the S&P 500 has only moved -12.73% and -11.46%, respectively.
Investors should also take note of UTHR's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, UTHR is averaging 456,331 shares for the last 20 days.
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with UTHR.
Over the past two months, 1 earnings estimate moved higher compared to 2 lower for the full year. These revisions helped boost UTHR's consensus estimate, increasing from $16.77 to $17.23 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been 3 downward revisions in the same time period.
Given these factors, it shouldn't be surprising that UTHR is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep United Therapeutics on your short list.